PubMed · 12901235
Cilengitide Merck.
Abstract
Merck KGaA is developing cilengitide, the lead in a series of integrin antagonists with anti-angiogenic activities, for the potential treatment of a variety of cancer types. The National Cancer Institute is conducting clinical trials of cilengitide. In October 1999, phase II trials in non-small-cell lung cancer (as a monotherapy) and pancreatic cancer (in combination with gemcitabine) were initiated. These were ongoing in February 2002, by which time, a phase I trial and a phase I/II trial in glioblastoma were underway.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Jeffrey W Smith. 2003. Cilengitide Merck.. https://pubmed.health/record/pubmed%3A12901235/cilengitide-merck
Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite PubMed Health by Indiciae: BibTeX · RIS.